Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04660396 · ClinicalTrials.gov registry record
Monitoring Outpatient Blood VolumE in Heart Failure
A clinical trial, sponsored by Daxor Corporation.
- Completed
- Registry status
- 15
- Enrollment target
NCT04660396: Completed study, sponsored by Daxor Corporation.
NCT04660396 is a clinical trial that has completed, run by Daxor Corporation. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04660396 has completed, sponsored by Daxor Corporation.
- COMPLETED
- Registry status
- 15 participants
- Enrollment target
Study Summary
In patients discharged following heart failure treatment, the consistency of blood volume status and components over time is unknown. The primary objective is to describe the rate of change, if any, of the plasma volume and red blood cell volume following hospitalization and discharge of patients with heart failure.
Primary Outcome
Accurately quantify changes to plasma volume and red blood cell volume in HF outpatients over the 12-week period following discharge.
Interventions
- DEVICE BVA-100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-09-16 |
| Est. Completion | 2022-07-30 |
What the finished NCT04660396 record still lists
NCT04660396 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 15 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which BVA-100 is the first listed.
NCT04660396 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04660396 about?
NCT04660396 is a clinical study titled "Monitoring Outpatient Blood VolumE in Heart Failure". In patients discharged following heart failure treatment, the consistency of blood volume status and components over time is unknown. The primary objective is to describe the rate of change, if any, of the plasma volume and red blood cell volume following hospitalization and discharge of patients wi...
What is the current status of trial NCT04660396?
This trial is currently completed. The enrollment target is 15 participants. The study started on 2021-09-16. Estimated completion is 2022-07-30.
What interventions are being tested in trial NCT04660396?
The interventions under investigation include: BVA-100 (DEVICE).
Who is sponsoring clinical trial NCT04660396?
This trial is sponsored by Daxor Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI